{"id":"W2894746763","doi":"10.1016/s0140-6736(18)32261-x","title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","year":2018,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":1791,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Institutes of Health; Sirtex Medical; Servier; Novo Nordisk; Boston Scientific Corporation; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; Daiichi Sankyo Europe; Sanofi; Abbott Laboratories","keywords":"Medicine; Placebo; Type 2 diabetes; Double blind; Disease; Internal medicine; Diabetes mellitus; Physical therapy; Alternative medicine; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}